{"id":1594,"date":"2026-08-10T10:00:22","date_gmt":"2026-08-10T10:00:22","guid":{"rendered":"https:\/\/newsraise.com\/in\/2026\/08\/10\/q-line-biotech-ipo-214-crore\/"},"modified":"2026-08-10T10:00:22","modified_gmt":"2026-08-10T10:00:22","slug":"q-line-biotech-ipo-214-crore","status":"publish","type":"post","link":"https:\/\/newsraise.com\/in\/2026\/08\/10\/q-line-biotech-ipo-214-crore\/","title":{"rendered":"Q-Line Biotech launches Rs 214.48\u2011crore IPO, offers 26.8% of post\u2011issue equity"},"content":{"rendered":"\n<!-- Quick Adsense WordPress Plugin: http:\/\/quickadsense.com\/ -->\n<div class=\"9fece8afa224fd09e54b043d0febfb58\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- NR ATF -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-8898941184964366\"\r\n     data-ad-slot=\"4839033563\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>Q-Line Biotech Ltd. (QBL), a developer and manufacturer of in\u2011vitro diagnostic (IVD) reagents, kits and point\u2011of\u2011care devices, announced a book\u2011building initial public offering of 6,253,200 equity shares at a face value of Rs\u202f10 each. The issue seeks to mobilise up to Rs\u202f214.48\u202fcrore, representing 26.81% of the company\u2019s post\u2011IPO paid\u2011up capital.<\/p>\n<h2>IPO pricing, timeline and allocation<\/h2>\n<p>The price band for the offering is set between Rs\u202f326 and Rs\u202f343 per share. Applicants must subscribe for a minimum of 800 shares, with subsequent applications in multiples of 400 shares. The subscription window opens on 21 May 2026 and closes on 25 May 2026. Upon listing, the shares will trade on the NSE SME Emerge platform.<\/p>\n<p>In a pre\u2011IPO placement earlier in May 2026, QBL raised Rs\u202f27.44\u202fcrore by selling 800,000 shares at the top of the price band, Rs\u202f343 per share. The issue is jointly lead\u2011managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd., with Purva Sharegistry (India) Pvt. Ltd. acting as registrar. Hem Finlease Pvt. Ltd., a member of the HEM group, serves as market maker and syndicate member.<\/p>\n<h2>Use of proceeds and capital structure<\/h2>\n<p>Net proceeds from the offering are earmarked for three primary purposes: Rs\u202f93.50\u202fcrore for working capital, Rs\u202f90.00\u202fcrore to repay or pre\u2011pay certain borrowings, and the remaining amount for general corporate purposes. After the issue, the company\u2019s paid\u2011up equity is expected to rise from Rs\u202f17.07\u202fcrore to Rs\u202f23.33\u202fcrore, implying a post\u2011issue market capitalisation of roughly Rs\u202f800.16\u202fcrore if the upper price band is achieved.<\/p>\n<p>Historically, QBL has issued equity at par value and has raised additional capital in price ranges of Rs\u202f125 to Rs\u202f417 between March 2019 and May 2026. Bonus issues were declared at a 2\u2011for\u20111 ratio in March 2016 and a 9\u2011for\u20111 ratio in August 2025. The average acquisition cost for promoters stands at Rs\u202f0.00, Rs\u202f0.04 and Rs\u202f18.34 per share for the respective issuances.<\/p>\n<h2>Business overview and recent financial performance<\/h2>\n<p>Founded in 2013, Q\u2011Line Biotech supplies diagnostic equipment and IVD products to hospitals, diagnostic service providers and medical colleges, either directly or through distributors. Its product portfolio spans clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and point\u2011of\u2011care devices. During the COVID\u201119 pandemic, the firm expanded its range to include RT\u2011PCR kits, RNA extraction kits and VTM kits through collaborations with third\u2011party institutes and internal R&#038;D.<\/p>\n<p>The company maintains a research\u2011driven model, leveraging in\u2011house R&#038;D and technical collaborations with international partners to manufacture reagents and equipment that meet stringent quality and certification standards. As of 31 March 2026, QBL employed 362 permanent staff and 223 contract workers, of whom 19 (5.25% of the permanent workforce) were stationed in R&#038;D laboratories.<\/p>\n<p>On a consolidated basis, QBL reported total income of Rs\u202f184.81\u202fcrore and net profit of Rs\u202f32.10\u202fcrore for FY\u202f2023; Rs\u202f206.45\u202fcrore and Rs\u202f34.44\u202fcrore respectively for FY\u202f2024; and Rs\u202f322.58\u202fcrore with a net profit of Rs\u202f28.13\u202fcrore for FY\u202f2025. For the nine\u2011month period ending 31 December 2025 (9M\u2011FY26), the company posted total income of Rs\u202f236.50\u202fcrore and a net profit of Rs\u202f38.69\u202fcrore, indicating a sharp increase in earnings compared with the full FY\u202f2025 results.<\/p>\n<p>Profit\u2011after\u2011tax (PAT) margins declined from 17.56% in FY\u202f2023 and 16.92% in FY\u202f2024 to 8.97% in FY\u202f2025, before rebounding to 16.65% in the 9M\u2011FY26 period. Return on net worth (RoNW) averaged Rs\u202f25.00 per share over FY\u202f2024\u201125, with an average RoNW of 23.17% across the last two fiscal years. The issue is priced at a price\u2011to\u2011book value (P\/BV) of 2.44 based on a NAV of Rs\u202f140.81 per share as of 31 December 2025; however, post\u2011IPO NAV figures are not disclosed in the offer documents.<\/p>\n<p>Using the FY\u202f2026 earnings proxy, the IPO price translates to a price\u2011to\u2011earnings (P\/E) multiple of 15.51, while the FY\u202f2025 earnings imply a P\/E of 28.44. Analysts in the source commentary suggest that the pricing reflects the strong nine\u2011month earnings, which may not be sustainable given the variability in profitability.<\/p>\n<p>The company has not declared dividends for any of the reported periods and states that any future dividend policy will be \u201cprudent,\u201d contingent on financial performance and outlook. No listed peers are identified for benchmarking purposes.<\/p>\n<h2>Market perception and analyst view<\/h2>\n<p>Two merchant bankers associated with the issue have collectively handled 79 issues over the past three years, of which eight closed below the issue price on listing day. The commentary accompanying the prospectus notes that, despite top\u2011line growth, QBL\u2019s bottom line showed a dip in FY\u202f2025 due to extraordinary items amounting to Rs\u202f16.97\u202fcrore and a contingent liability of Rs\u202f61.64\u202fcrore as of 31 December 2025. Overall borrowings stood at Rs\u202f242.57\u202fcrore at the same date, raising concerns about leverage.<\/p>\n<p>Given the absence of listed comparables and the company\u2019s reliance on a strong nine\u2011month earnings run\u2011rate to justify valuation, the review concludes that the issue appears fully priced. It recommends that well\u2011informed investors may allocate moderate funds for the long term, while remaining mindful of earnings sustainability and debt levels.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Q-Line Biotech Ltd. filed a book\u2011building IPO of 6.25\u202fmillion shares to raise up to Rs\u202f214.48\u202fcrore, with proceeds earmarked for working capital and debt repayment.<\/p>\n","protected":false},"author":2,"featured_media":1595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[299],"tags":[499,1371,1368,1370,1369],"class_list":["post-1594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-finance","tag-healthcare","tag-ipo","tag-ivd","tag-q-line-biotech","entry"],"_links":{"self":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/1594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/comments?post=1594"}],"version-history":[{"count":0,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/1594\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media\/1595"}],"wp:attachment":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media?parent=1594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/categories?post=1594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/tags?post=1594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}